全文获取类型
收费全文 | 907篇 |
免费 | 55篇 |
学科分类
医药卫生 | 962篇 |
出版年
2022年 | 4篇 |
2021年 | 19篇 |
2020年 | 9篇 |
2019年 | 10篇 |
2018年 | 23篇 |
2017年 | 18篇 |
2016年 | 16篇 |
2015年 | 24篇 |
2014年 | 27篇 |
2013年 | 33篇 |
2012年 | 49篇 |
2011年 | 48篇 |
2010年 | 34篇 |
2009年 | 21篇 |
2008年 | 42篇 |
2007年 | 39篇 |
2006年 | 54篇 |
2005年 | 44篇 |
2004年 | 59篇 |
2003年 | 56篇 |
2002年 | 54篇 |
2001年 | 35篇 |
2000年 | 35篇 |
1999年 | 38篇 |
1998年 | 12篇 |
1997年 | 8篇 |
1996年 | 4篇 |
1993年 | 3篇 |
1992年 | 7篇 |
1991年 | 7篇 |
1990年 | 5篇 |
1989年 | 7篇 |
1988年 | 3篇 |
1987年 | 9篇 |
1986年 | 5篇 |
1985年 | 6篇 |
1984年 | 3篇 |
1979年 | 6篇 |
1971年 | 3篇 |
1939年 | 3篇 |
1937年 | 3篇 |
1930年 | 6篇 |
1926年 | 7篇 |
1924年 | 8篇 |
1923年 | 2篇 |
1921年 | 3篇 |
1919年 | 3篇 |
1913年 | 2篇 |
1907年 | 2篇 |
1904年 | 2篇 |
排序方式: 共有962条查询结果,搜索用时 15 毫秒
31.
Ferdinand Mühlbacher Hans‐Helmut Neumayer Domingo del Castillo Sergio Stefoni Klemens Budde the European Rapamune Cyclosporine Minimization Study Group 《Transplant international》2014,27(2):176-186
This study evaluated the safety and efficacy of a sirolimus, corticosteroid, and cyclosporine reduction regimen in an open‐label, 12‐month trial of 420 de novo renal allograft recipients at 49 European transplant centers. One month post‐transplantation, 357 patients were randomized to receive standard‐dose cyclosporine (sCsA, n = 179) or reduced‐dose cyclosporine (rCsA, n = 178). All patients also received sirolimus and corticosteroids. The primary end points were the rate of biopsy‐confirmed acute rejection (BCAR) and renal function, as measured by serum creatinine. Baseline demographic and donor characteristics were similar between groups. BCAR rates at 12 months were not significantly different: 11.2% for rCsA patients and 16.2% for sCsA patients. Mean serum creatinine (±SEM) was significantly lower (1.75 ± 0.10 vs. 1.97 ± 0.07 mg/dl, P < 0.001), and creatinine clearance (±SEM; Nankivell method) was significantly higher (57.8 ± 1.78 vs. 49.5 ± 2.46 ml/min, P < 0.001) in patients receiving rCsA versus sCsA at 1 year, respectively. Patient and graft survival exceeded 98% in both groups. No significant differences in infection or malignancy were noted between groups. The rCsA with sirolimus and corticosteroid regimen resulted in excellent 12‐month patient and graft survival, a low incidence of BCAR, and improved renal function in renal allograft recipients. Sirolimus administered with rCsA and corticosteroids provided adequate immunosuppression while reducing the potential for the nephrotoxic effects of cyclosporine. These findings may help to improve long‐term renal allograft outcomes. 相似文献
32.
33.
Wiebe G Knol Ali R Wahadat Jolien W Roos-Hesselink Nicolas M Van Mieghem Wilco Tanis Ad J J C Bogers Ricardo P J Budde 《Interactive Cardiovascular and Thoracic Surgery》2021,32(4):522
OBJECTIVESIn patients with unknown coronary status undergoing surgery for acute infective endocarditis (IE), the need to screen for coronary artery disease (CAD) and the risk of embolization during invasive coronary angiography (ICA) are debated. Coronary computed tomography angiography (CCTA) is a non-invasive alternative in these patients. We aimed to evaluate the safety and feasibility of ICA and CCTA to diagnose CAD, and the necessity to treat CAD to prevent CAD-related postoperative complications. Open in a separate windowMETHODSIn this single-centre retrospective cohort study, all patients with acute aortic IE between 2009 and 2019 undergoing surgery were selected. Outcomes were any clinically evident embolization after preoperative ICA, in-hospital mortality, perioperative myocardial infarction or unplanned revascularization and postoperative renal function.RESULTSOf the 159 included patients, CAD status was already known in 14. No preoperative diagnostics for CAD was done in 46/145, a CCTA was performed in 54/145 patients and an ICA in 52/145 patients. Significant CAD was found after CCTA in 22% and after ICA in 21% of patients. In 1 of the 52 (2%) patients undergoing preoperative ICA, a cerebral embolism occurred. The rate of perioperative myocardial infarction or unplanned revascularization in patients not screened for CAD was 2% (1 out of 46 patients).CONCLUSIONSAlthough the risk of embolism after preoperative ICA is low, it should be carefully weighed against the estimated risk of CAD-related perioperative complications. CCTA can serve as a gatekeeper for ICA in most patients with acute aortic IE. 相似文献
34.
Kathrin Brmmel Christian Paul Konken Frederik Brgel Henry Obeng-Darko Sonja Schelhaas Etmar Bulk Thomas Budde Albrecht Schwab Michael Schfers Bernhard Wünsch 《RSC advances》2021,11(48):30295
Expression of the Ca2+ activated potassium channel 3.1 (KCa3.1) channel (also known as the Gàrdos channel) is dysregulated in many tumor entities and has predictive power with respect to patient survival. Therefore, a positron emission tomography (PET) tracer targeting this ion channel could serve as a potential diagnostic tool by imaging the KCa3.1 channel in vivo. It was envisaged to synthesize [18F]senicapoc ([18F]1) since senicapoc (1) shows high affinity and excellent selectivity towards the KCa3.1 channels. Because problems occurred during 18F-fluorination, the [18F]fluoroethoxy senicapoc derivative [18F]28 was synthesized to generate an alternative PET tracer targeting the KCa3.1 channel. Inhibition of the KCa3.1 channel by 28 was confirmed by patch clamp experiments. In vitro stability in mouse and human serum was shown for 28. Furthermore, biodistribution experiments in wild type mice were performed. Since [18F]fluoride was detected in vivo after application of [18F]28, an in vitro metabolism study was conducted. A potential degradation route of fluoroethoxy derivatives in vivo was found which in general should be taken into account when designing new PET tracers for different targets with a [18F]fluoroethoxy moiety as well as when using the popular prosthetic group [18F]fluoroethyl tosylate for the alkylation of phenols.Expression of the Ca2+ activated potassium channel 3.1 (KCa3.1) channel (also known as the Gàrdos channel) is dysregulated in many tumor entities and has predictive power with respect to patient survival. 相似文献
35.
36.
37.
Ostertag Junius Jacob Gerd Peters Mende Lindenberg Lenart K. Rintelen Wirth Max Budde Dietrich Blos Sonntag B. Haager de Veer Hill Sunder-Plassmann 《Journal of cancer research and clinical oncology》1942,53(3-4):230-236
Ohne Zusammenfassung 相似文献
38.
Georg Lange Strobel Sponholz Werthemann Spaar Max Budde 《Journal of cancer research and clinical oncology》1939,49(4):167-171
Ohne Zusammenfassung 相似文献
39.
Budde K Knoll G Curtis J Chan L Pohanka E Gentil M Seifu Y Marrast AC Neumayer HH;ERL B Study Group 《Clinical nephrology》2006,66(2):103-111
AIM: A 12-month multicenter, double-blind trial in which maintenance renal transplant patients were randomized to remain on mycophenolate mofetil (MMF) or convert to enteric-coated mycophenolate sodium (EC-MPS, myfortic) has demonstrated that conversion from MMF to EC-MPS is safe. Patients completing the study were invited to enter an open-label extension. Upon entry to the extension, patients who had received MMF during the randomized phase were converted to EC-MPS ("newly-exposed EC-MPS" group) and were monitored separately from those who had been randomized to EC-MPS ("long-term EC-MPS" group). The aim of the extension study was to collect long-term safety and efficacy data on EC-MPS, and to confirm the safety of conversion from MMF to EC-MPS in a larger patient population. METHODS: All patients received EC-MPS 720 mg b.i.d. with cyclosporine microemulsion and corticosteroids per local practice. Data derived from the analysis of the first 24 months of the extension phase are presented. RESULTS: Of the 297 patients who completed the core study, 260 (88%) entered the extension; 195 (75%) completed the 24-month extension visit. For on-treatment patients > 95% of the planned daily dose of EC-MPS was administered, and < 13% of patients in both groups had discontinued EC-MPS due to adverse events by 24 months. The overall incidence of adverse events during the extension phase, including infections and hematological abnormalities, was comparable to that seen in the core study, with a similar safety profile in the newly-exposed and long-term EC-MPS groups. There were 3 deaths during the first 24 months of the extension, and 2 graft failures in both the "newly-exposed" and "long-term" EC-MPS groups. CONCLUSIONS: These data demonstrate that long-term use of EC-MPS is effective and has an acceptable tolerability profile in renal transplant patients, and confirm that conversion of maintenance renal transplant patients from MMF to EC-MPS is a safe therapeutic option. 相似文献
40.
Eva Schrezenmeier Lukas J. Lehner Marina Merkel Manuel Mayrdorfer Wiebke Duettmann Marcel G. Naik Felix Fröhlich Lutz Liefeldt Mareen Pigorsch Frank Friedersdorff Danilo Schmidt Matthias Niemann Nils Lachmann Klemens Budde Fabian Halleck 《Transplant international》2021,34(4):732-742
The number of patients returning to dialysis after graft failure increases. Surprisingly, little is known about the clinical and immunological outcomes of this cohort. We retrospectively analyzed 254 patients after kidney allograft loss between 1997 and 2017 and report clinical outcomes such as mortality, relisting, retransplantations, transplant nephrectomies, and immunization status. Of the 254 patients, 49% had died 5 years after graft loss, while 27% were relisted, 14% were on dialysis and not relisted, and only 11% were retransplanted 5 years after graft loss. In the complete observational period, 111/254 (43.7%) patients were relisted. Of these, 72.1% of patients were under 55 years of age at time of graft loss and only 13.5% of patients were ≥65 years. Age at graft loss was associated with relisting in a logistic regression analysis. In the complete observational period, 42 patients (16.5%) were retransplanted. Only 4 of those (9.5%) were ≥65 years at time of graft loss. Nephrectomy had no impact on survival, relisting, or development of dnDSA. Patients after allograft loss have a high overall mortality. Immunization contributes to long waiting times. Only a very limited number of patients are retransplanted especially when ≥65 years at time of graft loss. 相似文献